MicroRNA-guided tumor-specific induction of KYAT1 in combination with the non-toxic prodrug (MSC) has a great potential in the treatment of cancers that are currently beyond cure such as HCC. This evidence concerns the gene KYAT1 and hepatocellular carcinoma.